dr. gulley discusses a phase ii study of olaparib and durvalumab in mcrpc
Published 6 years ago • 261 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
1:00
dr. gulley on take home message with olaparib plus durvalumab in mcrpc
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
4:30
profound: olaparib for hrr mcrpc
-
1:38
dr. morgan on olaparib for metastatic castration-resistant prostate cancer
-
16:07
profound trial shows increased rpfs in mcrpc patients with brca1, brca2, and atm mutations
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
1:40
dr. maughan discusses abiraterone plus olaparib in mcrpc
-
1:43
dr. sonpavde discusses a study of fixed-dose durvalumab and tremelimumab in urothelial carcinoma
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
0:53
dr. annunziata on olaparib and cediranib combination in ovarian cancer
-
1:22
dr. pusztai on rationale for the i-spy 2 trial with durvalumab/olaparib combo in her2- breast cancer
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
1:40
safety results from phase 3b strong trial of durvalumab in patients with urinary tract carcinoma
-
1:32
dr. chang discusses the use of parp inhibitors in prostate cancer
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
1:56
dr. antonarakis on sipuleucel-t plus radium-223 in bone-metastatic crpc
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc